Clarient has launched its Insight Dx Pulmonary test to help classify non-small cell lung cancer (NSCLC) patients. It is now available as a lab-developed test under CLIA-regulations. The diagnostic differentiates between adenocarcinoma and squamous cell carcinoma NSCLC subtypes, ...
Please Login to read the full article.
